Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 48 of 756 entries
Sorted by: Best Match Show Resources per page
Anthracycline dose intensification in young adults with acute myeloid leukemia.

Therapeutic advances in hematology

Padron E, Fernandez H.
PMID: 23556109
Ther Adv Hematol. 2012 Feb;3(1):17-27. doi: 10.1177/2040620711427069.

The initial treatment for acute myeloid leukemia (AML) has remained largely unchanged for nearly 40 years. Our growing understanding of the molecular pathology of AML has resulted in improved measures to risk stratify patients by recurrent cytogenetic and molecular...

Cite
Padron E, Fernandez H. Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol. 2012;3(1):17-27doi: 10.1177/2040620711427069.
Padron, E., & Fernandez, H. (2012). Anthracycline dose intensification in young adults with acute myeloid leukemia. Therapeutic advances in hematology, 3(1), 17-27. https://doi.org/10.1177/2040620711427069
Padron, Eric, and Fernandez, Hugo. "Anthracycline dose intensification in young adults with acute myeloid leukemia." Therapeutic advances in hematology vol. 3,1 (2012): 17-27. doi: https://doi.org/10.1177/2040620711427069
Padron E, Fernandez H. Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol. 2012 Feb;3(1):17-27. doi: 10.1177/2040620711427069. PMID: 23556109; PMCID: PMC3573430.
Copy Download .nbib Format: NLM
Paradoxical Immune Reconstitution Syndrome Presenting as Acute Respiratory Distress Syndrome in a Leukemia Patient during Neutrophil Recovery.

Case reports in hematology

Alawin IA, Karnath BM.
PMID: 22928127
Case Rep Hematol. 2012;2012:670347. doi: 10.1155/2012/670347. Epub 2012 Jun 11.

Immune reconstitution inflammatory syndrome (IRIS) in the setting of antiretroviral therapy is well described, but it is not as common in non-HIV patients; here, we present a case of immune reconstitution inflammatory syndrome presenting as acute respiratory distress syndrome...

Cite
Alawin IA, Karnath BM. Paradoxical Immune Reconstitution Syndrome Presenting as Acute Respiratory Distress Syndrome in a Leukemia Patient during Neutrophil Recovery. Case Rep Hematol. 2012;2012:670347doi: 10.1155/2012/670347.
Alawin, I. A., & Karnath, B. M. (2012). Paradoxical Immune Reconstitution Syndrome Presenting as Acute Respiratory Distress Syndrome in a Leukemia Patient during Neutrophil Recovery. Case reports in hematology, 2012670347. https://doi.org/10.1155/2012/670347
Alawin, Issam A, and Karnath, Bernard M. "Paradoxical Immune Reconstitution Syndrome Presenting as Acute Respiratory Distress Syndrome in a Leukemia Patient during Neutrophil Recovery." Case reports in hematology vol. 2012 (2012): 670347. doi: https://doi.org/10.1155/2012/670347
Alawin IA, Karnath BM. Paradoxical Immune Reconstitution Syndrome Presenting as Acute Respiratory Distress Syndrome in a Leukemia Patient during Neutrophil Recovery. Case Rep Hematol. 2012;2012:670347. doi: 10.1155/2012/670347. Epub 2012 Jun 11. PMID: 22928127; PMCID: PMC3420500.
Copy Download .nbib Format: NLM
Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case.

Case reports in hematology

Regragui S, Amelal S, Astati S, Zine M, Alami Drideb N, Al Bouzidi A, Messaoudi N, Benkirane M, Doghmi K, Mikdame M.
PMID: 22953078
Case Rep Hematol. 2012;2012:806476. doi: 10.1155/2012/806476. Epub 2012 May 07.

The thrombotic microangiopathy is a syndrome characterized by the combination of mechanical hemolytic anemia, peripheral thrombocytopenia, and organ failure of variable severity. In addition to the idiopathic form, several cases are identified as secondary to pregnancy, infections, disease systems,...

Cite
Regragui S, Amelal S, Astati S, et al. Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case. Case Rep Hematol. 2012;2012:806476doi: 10.1155/2012/806476.
Regragui, S., Amelal, S., Astati, S., Zine, M., Alami Drideb, N., Al Bouzidi, A., Messaoudi, N., Benkirane, M., Doghmi, K., & Mikdame, M. (2012). Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case. Case reports in hematology, 2012806476. https://doi.org/10.1155/2012/806476
Regragui, S, et al. "Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case." Case reports in hematology vol. 2012 (2012): 806476. doi: https://doi.org/10.1155/2012/806476
Regragui S, Amelal S, Astati S, Zine M, Alami Drideb N, Al Bouzidi A, Messaoudi N, Benkirane M, Doghmi K, Mikdame M. Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case. Case Rep Hematol. 2012;2012:806476. doi: 10.1155/2012/806476. Epub 2012 May 07. PMID: 22953078; PMCID: PMC3420723.
Copy Download .nbib Format: NLM
Intravascular Lymphoma in the CNS: Options for Treatment.

Current treatment options in neurology

Nizamutdinov D, Patel NP, Huang JH, Fonkem E.
PMID: 28831736
Curr Treat Options Neurol. 2017 Aug 23;19(10):35. doi: 10.1007/s11940-017-0471-4.

Purpose of review The purpose of this review was to discuss therapeutic manipulations and effective current interventions available to treat intravascular lymphoma in the central nervous system. Recent findings Patients experienced resolution and remission of disease for 14 months...

Cite
Nizamutdinov D, Patel NP, Huang JH, et al. Intravascular Lymphoma in the CNS: Options for Treatment. Curr Treat Options Neurol. 2017;19(10):35doi: 10.1007/s11940-017-0471-4.
Nizamutdinov, D., Patel, N. P., Huang, J. H., & Fonkem, E. (2017). Intravascular Lymphoma in the CNS: Options for Treatment. Current treatment options in neurology, 19(10), 35. https://doi.org/10.1007/s11940-017-0471-4
Nizamutdinov, Damir, et al. "Intravascular Lymphoma in the CNS: Options for Treatment." Current treatment options in neurology vol. 19,10 (2017): 35. doi: https://doi.org/10.1007/s11940-017-0471-4
Nizamutdinov D, Patel NP, Huang JH, Fonkem E. Intravascular Lymphoma in the CNS: Options for Treatment. Curr Treat Options Neurol. 2017 Aug 23;19(10):35. doi: 10.1007/s11940-017-0471-4. PMID: 28831736; PMCID: PMC5569665.
Copy Download .nbib Format: NLM
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Frontiers in oncology

Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M.
PMID: 30319961
Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018.

No abstract available.

Cite
Boddu P, Borthakur G, Koneru M, et al. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018;8:369doi: 10.3389/fonc.2018.00369.
Boddu, P., Borthakur, G., Koneru, M., Huang, X., Naqvi, K., Wierda, W., Bose, P., Jabbour, E., Estrov, Z., Burger, J., Alvarado, Y., Deshmukh, A., Patel, A., Cavazos, A., Han, L., Cortes, J. E., Kantarjian, H., Andreeff, M., & Konopleva, M. (2018). Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Frontiers in oncology, 8369. https://doi.org/10.3389/fonc.2018.00369
Boddu, Prajwal, et al. "Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia." Frontiers in oncology vol. 8 (2018): 369. doi: https://doi.org/10.3389/fonc.2018.00369
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018. PMID: 30319961; PMCID: PMC6167965.
Copy Download .nbib Format: NLM
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.

Signal transduction and targeted therapy

Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, Chen K, Lin H, Taub JW, Ge Y.
PMID: 29263915
Signal Transduct Target Ther. 2017 Apr 07;2:17012. doi: 10.1038/sigtrans.2017.12. eCollection 2017.

Acute myeloid leukemia (AML) is a serious disease. The 5-year survival rates remain frustratingly low (65% for children and 26% for adults). Resistance to frontline chemotherapy (usually cytarabine) often develops; therefore a new treatment modality is needed. Bcl-2 family...

Cite
Luedtke DA, Niu X, Pan Y, et al. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct Target Ther. 2017;2:17012doi: 10.1038/sigtrans.2017.12.
Luedtke, D. A., Niu, X., Pan, Y., Zhao, J., Liu, S., Edwards, H., Chen, K., Lin, H., Taub, J. W., & Ge, Y. (2017). Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal transduction and targeted therapy, 217012. https://doi.org/10.1038/sigtrans.2017.12
Luedtke, Daniel A, et al. "Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells." Signal transduction and targeted therapy vol. 2 (2017): 17012. doi: https://doi.org/10.1038/sigtrans.2017.12
Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, Chen K, Lin H, Taub JW, Ge Y. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct Target Ther. 2017 Apr 07;2:17012. doi: 10.1038/sigtrans.2017.12. eCollection 2017. PMID: 29263915; PMCID: PMC5661618.
Copy Download .nbib Format: NLM
A desensitization protocol for delayed allergy to cytarabine: analysis of two cases.

Postepy dermatologii i alergologii

Albanesi M, Carluccio P, Nico A, Giliberti L, Di Bona D, Caiaffa MF, Specchia G, Macchia L.
PMID: 29760627
Postepy Dermatol Alergol. 2018 Apr;35(2):222-224. doi: 10.5114/ada.2018.75249. Epub 2018 Apr 24.

No abstract available.

Cite
Albanesi M, Carluccio P, Nico A, et al. A desensitization protocol for delayed allergy to cytarabine: analysis of two cases. Postepy Dermatol Alergol. 2018;35(2):222-224doi: 10.5114/ada.2018.75249.
Albanesi, M., Carluccio, P., Nico, A., Giliberti, L., Di Bona, D., Caiaffa, M. F., Specchia, G., & Macchia, L. (2018). A desensitization protocol for delayed allergy to cytarabine: analysis of two cases. Postepy dermatologii i alergologii, 35(2), 222-224. https://doi.org/10.5114/ada.2018.75249
Albanesi, Marcello, et al. "A desensitization protocol for delayed allergy to cytarabine: analysis of two cases." Postepy dermatologii i alergologii vol. 35,2 (2018): 222-224. doi: https://doi.org/10.5114/ada.2018.75249
Albanesi M, Carluccio P, Nico A, Giliberti L, Di Bona D, Caiaffa MF, Specchia G, Macchia L. A desensitization protocol for delayed allergy to cytarabine: analysis of two cases. Postepy Dermatol Alergol. 2018 Apr;35(2):222-224. doi: 10.5114/ada.2018.75249. Epub 2018 Apr 24. PMID: 29760627; PMCID: PMC5949556.
Copy Download .nbib Format: NLM
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism.

Journal of cellular and molecular medicine

Stroopinsky D, Rajabi H, Nahas M, Rosenblatt J, Rahimian M, Pyzer A, Tagde A, Kharbanda A, Jain S, Kufe T, Leaf RK, Anastasiadou E, Bar-Natan M, Orr S, Coll MD, Palmer K, Ephraim A, Cole L, Washington A, Kufe D, Avigan D.
PMID: 29761849
J Cell Mol Med. 2018 May 15; doi: 10.1111/jcmm.13662. Epub 2018 May 15.

Acute myeloid leukaemia (AML) is an aggressive haematological malignancy with an unmet need for improved therapies. Responses to standard cytotoxic therapy in AML are often transient because of the emergence of chemotherapy-resistant disease. The MUC1-C oncoprotein governs critical pathways...

Cite
Stroopinsky D, Rajabi H, Nahas M, et al. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. J Cell Mol Med. 2018;doi: 10.1111/jcmm.13662.
Stroopinsky, D., Rajabi, H., Nahas, M., Rosenblatt, J., Rahimian, M., Pyzer, A., Tagde, A., Kharbanda, A., Jain, S., Kufe, T., Leaf, R. K., Anastasiadou, E., Bar-Natan, M., Orr, S., Coll, M. D., Palmer, K., Ephraim, A., Cole, L., Washington, A., Kufe, D., & Avigan, D. (2018). MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. Journal of cellular and molecular medicine, . https://doi.org/10.1111/jcmm.13662
Stroopinsky, Dina, et al. "MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism." Journal of cellular and molecular medicine vol. (2018). doi: https://doi.org/10.1111/jcmm.13662
Stroopinsky D, Rajabi H, Nahas M, Rosenblatt J, Rahimian M, Pyzer A, Tagde A, Kharbanda A, Jain S, Kufe T, Leaf RK, Anastasiadou E, Bar-Natan M, Orr S, Coll MD, Palmer K, Ephraim A, Cole L, Washington A, Kufe D, Avigan D. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. J Cell Mol Med. 2018 May 15; doi: 10.1111/jcmm.13662. Epub 2018 May 15. PMID: 29761849; PMCID: PMC6050463.
Copy Download .nbib Format: NLM
Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells.

Frontiers in pharmacology

Renner K, Seilbeck A, Kauer N, Ugele I, Siska PJ, Brummer C, Bruss C, Decking SM, Fante M, Schmidt A, Hammon K, Singer K, Klobuch S, Thomas S, Gottfried E, Peter K, Kreutz M.
PMID: 30450049
Front Pharmacol. 2018 Nov 02;9:1258. doi: 10.3389/fphar.2018.01258. eCollection 2018.

The accelerated metabolism of tumor cells, inevitable for maintaining high proliferation rates, is an emerging target for tumor therapy. Increased glucose and lipid metabolism as well as mitochondrial activity have been shown in solid tumors but also in leukemic...

Cite
Renner K, Seilbeck A, Kauer N, et al. Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells. Front Pharmacol. 2018;9:1258doi: 10.3389/fphar.2018.01258.
Renner, K., Seilbeck, A., Kauer, N., Ugele, I., Siska, P. J., Brummer, C., Bruss, C., Decking, S. M., Fante, M., Schmidt, A., Hammon, K., Singer, K., Klobuch, S., Thomas, S., Gottfried, E., Peter, K., & Kreutz, M. (2018). Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells. Frontiers in pharmacology, 91258. https://doi.org/10.3389/fphar.2018.01258
Renner, Kathrin, et al. "Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells." Frontiers in pharmacology vol. 9 (2018): 1258. doi: https://doi.org/10.3389/fphar.2018.01258
Renner K, Seilbeck A, Kauer N, Ugele I, Siska PJ, Brummer C, Bruss C, Decking SM, Fante M, Schmidt A, Hammon K, Singer K, Klobuch S, Thomas S, Gottfried E, Peter K, Kreutz M. Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells. Front Pharmacol. 2018 Nov 02;9:1258. doi: 10.3389/fphar.2018.01258. eCollection 2018. PMID: 30450049; PMCID: PMC6224440.
Copy Download .nbib Format: NLM
A patient with chronic myeloid leukemia and situs inversus totalis: A case report.

Oncology letters

Sun Y, Li X, Li L, Liu H, Xu Q, Liu B.
PMID: 29344183
Oncol Lett. 2017 Dec;14(6):7425-7430. doi: 10.3892/ol.2017.7166. Epub 2017 Oct 10.

In the present study, a case of chronic myeloid leukemia (CML) with complete situs inversus in a 68-year-old female patient was reported. The patient presented with general weakness, abdominal distension and tenderness in the right hypochondrium. A chest X-ray...

Cite
Sun Y, Li X, Li L, et al. A patient with chronic myeloid leukemia and situs inversus totalis: A case report. Oncol Lett. 2017;14(6):7425-7430doi: 10.3892/ol.2017.7166.
Sun, Y., Li, X., Li, L., Liu, H., Xu, Q., & Liu, B. (2017). A patient with chronic myeloid leukemia and situs inversus totalis: A case report. Oncology letters, 14(6), 7425-7430. https://doi.org/10.3892/ol.2017.7166
Sun, Yunxia, et al. "A patient with chronic myeloid leukemia and situs inversus totalis: A case report." Oncology letters vol. 14,6 (2017): 7425-7430. doi: https://doi.org/10.3892/ol.2017.7166
Sun Y, Li X, Li L, Liu H, Xu Q, Liu B. A patient with chronic myeloid leukemia and situs inversus totalis: A case report. Oncol Lett. 2017 Dec;14(6):7425-7430. doi: 10.3892/ol.2017.7166. Epub 2017 Oct 10. PMID: 29344183; PMCID: PMC5755252.
Copy Download .nbib Format: NLM
3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression.

Experimental and therapeutic medicine

Guo J, Zhao C, Yao R, Sui A, Sun L, Liu X, Wu S, Su Z, Li T, Liu S, Gao Y, Liu J, Feng X, Wang W, Zhao H, Cui Z, Li G, Meng F.
PMID: 30783426
Exp Ther Med. 2019 Mar;17(3):1593-1600. doi: 10.3892/etm.2019.7153. Epub 2019 Jan 04.

Three dimensional (3D) culture has gradually become a research hotspot in the field of drug screening, stem cell research, and tissue engineering due to its more physiological-like morphology and function. In this study, we compared the differences of cell...

Cite
Guo J, Zhao C, Yao R, et al. 3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression. Exp Ther Med. 2019;17(3):1593-1600doi: 10.3892/etm.2019.7153.
Guo, J., Zhao, C., Yao, R., Sui, A., Sun, L., Liu, X., Wu, S., Su, Z., Li, T., Liu, S., Gao, Y., Liu, J., Feng, X., Wang, W., Zhao, H., Cui, Z., Li, G., & Meng, F. (2019). 3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression. Experimental and therapeutic medicine, 17(3), 1593-1600. https://doi.org/10.3892/etm.2019.7153
Guo, Jun, et al. "3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression." Experimental and therapeutic medicine vol. 17,3 (2019): 1593-1600. doi: https://doi.org/10.3892/etm.2019.7153
Guo J, Zhao C, Yao R, Sui A, Sun L, Liu X, Wu S, Su Z, Li T, Liu S, Gao Y, Liu J, Feng X, Wang W, Zhao H, Cui Z, Li G, Meng F. 3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression. Exp Ther Med. 2019 Mar;17(3):1593-1600. doi: 10.3892/etm.2019.7153. Epub 2019 Jan 04. PMID: 30783426; PMCID: PMC6364197.
Copy Download .nbib Format: NLM
An Unusual Coexistence of Primary Central Nervous System Non-Hodgkin's Lymphoma and Acute Promyelocytic Leukemia.

Case reports in hematology

Fracchiolla NS, Sciumè M, Cernuschi G, Cortelezzi A.
PMID: 30662778
Case Rep Hematol. 2018 Dec 19;2018:2741939. doi: 10.1155/2018/2741939. eCollection 2018.

Acute promyelocytic leukemia and primary central nervous system lymphoma are uncommon hematological malignancies. The co-occurrence of acute myeloid leukemia with various lymphoproliferative diseases is an extremely rare condition, especially in the absence of previous chemotherapy or radiotherapy. Herein, we...

Cite
Fracchiolla NS, Sciumè M, Cernuschi G, et al. An Unusual Coexistence of Primary Central Nervous System Non-Hodgkin's Lymphoma and Acute Promyelocytic Leukemia. Case Rep Hematol. 2018;2018:2741939doi: 10.1155/2018/2741939.
Fracchiolla, N. S., Sciumè, M., Cernuschi, G., & Cortelezzi, A. (2018). An Unusual Coexistence of Primary Central Nervous System Non-Hodgkin's Lymphoma and Acute Promyelocytic Leukemia. Case reports in hematology, 20182741939. https://doi.org/10.1155/2018/2741939
Fracchiolla, Nicola Stefano, et al. "An Unusual Coexistence of Primary Central Nervous System Non-Hodgkin's Lymphoma and Acute Promyelocytic Leukemia." Case reports in hematology vol. 2018 (2018): 2741939. doi: https://doi.org/10.1155/2018/2741939
Fracchiolla NS, Sciumè M, Cernuschi G, Cortelezzi A. An Unusual Coexistence of Primary Central Nervous System Non-Hodgkin's Lymphoma and Acute Promyelocytic Leukemia. Case Rep Hematol. 2018 Dec 19;2018:2741939. doi: 10.1155/2018/2741939. eCollection 2018. PMID: 30662778; PMCID: PMC6313991.
Copy Download .nbib Format: NLM
Showing 37 to 48 of 756 entries